Skip to main content
VERU
NASDAQ Life Sciences

Veru Reports Narrowed Q2 Loss, Boosts Cash to $27.6M, and Advances Obesity Trial

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$2.31
Mkt Cap
$36.434M
52W Low
$2.06
52W High
$7.4
52W Position info
12% above low
Off High info
69% below high
Rel. Volume info
1.0× avg
Market data snapshot near publication time

VERU is trading near its 52-week low of $2.06 (12% above the low).

Summary

Veru Inc. announced a narrowed Q2 net loss and a significant increase in cash to $27.6 million, bolstering its financial position and advancing its key obesity clinical trial.


Key Events · Earnings and Guidance · VERU

  • Narrowed Net Loss

    The company reported a net loss of $2.7 million, or $0.12 per share, for Q2 fiscal 2026, a significant reduction from $7.9 million, or $0.54 per share, in the prior year.

  • Substantial Cash Increase

    Cash, cash equivalents, and restricted cash increased to $27.6 million as of March 31, 2026, up from $15.8 million on September 30, 2025. This increase was largely due to $23.3 million in financing activities.

  • Addressing Going Concern

    The significant cash infusion and improved liquidity directly address the 'going concern' warning previously disclosed, providing critical financial runway for operations and clinical development.

  • Clinical Trial Progress

    The Phase 2b PLATEAU clinical trial, evaluating enobosarm in combination with semaglutide for obesity, is actively enrolling patients and remains on track for an interim analysis in Q1 calendar year 2027.


Analysis · VERU · Life Sciences

Veru Inc. reported a significantly narrowed net loss for Q2 fiscal 2026 and a substantial increase in its cash reserves to $27.6 million, primarily driven by $23.3 million in financing activities. This improved liquidity directly addresses the company's previously disclosed 'going concern' warning and provides crucial runway for its clinical programs. The progress in the Phase 2b PLATEAU clinical trial for enobosarm, with interim analysis expected in Q1 2027, provides a positive operational update.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, VERU was trading at $2.31 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $36.4M. The 52-week trading range was $2.06 to $7.40. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

VERU - Latest Insights

VERU
Sep 08, 2026, 8:17 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $2.82
Real-time Price: $1.93 info
Change: -$0.890 (-32%) info
Market Cap: $33.078M info
VERU
Sep 08, 2026, 8:17 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $2.81
Real-time Price: $1.93 info
Change: -$0.880 (-31%) info
Market Cap: $33.078M info
VERU
Aug 10, 2026, 8:51 AM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $2.45
Real-time Price: $1.93 info
Change: -$0.520 (-21%) info
Market Cap: $33.078M info
VERU
Aug 10, 2026, 7:00 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $2.41
Real-time Price: $1.93 info
Change: -$0.4782 (-20%) info
Market Cap: $33.078M info
VERU
Aug 10, 2026, 6:30 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $2.29
Real-time Price: $1.93 info
Change: -$0.360 (-16%) info
Market Cap: $33.078M info